Advertisement
COO vs RGEN
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is COO is a StrongBuy and RGEN is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
COO’s FA Score shows that 0 FA rating(s) are green whileRGEN’s FA Score has 0 green FA rating(s).
- COO’s FA Score: 0 green, 5 red.
- RGEN’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
COO’s TA Score shows that 4 TA indicator(s) are bullish while RGEN’s TA Score has 5 bullish TA indicator(s).
- COO’s TA Score: 4 bullish, 6 bearish.
- RGEN’s TA Score: 5 bullish, 3 bearish.
Price Growth
COO (@Pharmaceuticals: Other) experienced а -11.58% price change this week, while RGEN (@Pharmaceuticals: Other) price change was +2.11% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +3.91%. For the same industry, the average monthly price growth was +4.90%, and the average quarterly price growth was +15.22%.
Reported Earning Dates
COO is expected to report earnings on Dec 04, 2025.
RGEN is expected to report earnings on Nov 04, 2025.
Industries' Descriptions
@Pharmaceuticals: Other (+3.91% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| COO | RGEN | COO / RGEN | |
| Capitalization | 12.9B | 6.87B | 188% |
| EBITDA | 1.1B | 99.5M | 1,105% |
| Gain YTD | -29.751 | -15.124 | 197% |
| P/E Ratio | 31.66 | 511.11 | 6% |
| Revenue | 3.99B | 674M | 592% |
| Total Cash | 116M | 709M | 16% |
| Total Debt | 2.59B | 686M | 377% |
COO | RGEN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 61 | 54 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 76 Overvalued | 95 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 63 | 78 | |
P/E GROWTH RATING 1..100 | 100 | 100 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
COO's Valuation (76) in the Medical Specialties industry is in the same range as RGEN (95) in the Biotechnology industry. This means that COO’s stock grew similarly to RGEN’s over the last 12 months.
COO's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as RGEN (100) in the Biotechnology industry. This means that COO’s stock grew similarly to RGEN’s over the last 12 months.
COO's SMR Rating (100) in the Medical Specialties industry is in the same range as RGEN (100) in the Biotechnology industry. This means that COO’s stock grew similarly to RGEN’s over the last 12 months.
COO's Price Growth Rating (63) in the Medical Specialties industry is in the same range as RGEN (78) in the Biotechnology industry. This means that COO’s stock grew similarly to RGEN’s over the last 12 months.
COO's P/E Growth Rating (100) in the Medical Specialties industry is in the same range as RGEN (100) in the Biotechnology industry. This means that COO’s stock grew similarly to RGEN’s over the last 12 months.
| COO | RGEN | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 61% | N/A |
| Stochastic ODDS (%) | 1 day ago 56% | 1 day ago 82% |
| Momentum ODDS (%) | 1 day ago 57% | 1 day ago 72% |
| MACD ODDS (%) | 1 day ago 57% | 1 day ago 82% |
| TrendWeek ODDS (%) | 1 day ago 59% | 1 day ago 74% |
| TrendMonth ODDS (%) | 1 day ago 59% | 1 day ago 79% |
| Advances ODDS (%) | 3 days ago 60% | 17 days ago 75% |
| Declines ODDS (%) | 9 days ago 59% | 3 days ago 81% |
| BollingerBands ODDS (%) | 1 day ago 51% | N/A |
| Aroon ODDS (%) | 1 day ago 65% | 1 day ago 78% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| IGOV | 42.43 | 0.25 | +0.59% |
| iShares International Treasury Bond ETF | |||
| CMCI | 25.37 | 0.11 | +0.43% |
| VanEck® CMCI Commodity Strategy ETF | |||
| PNF | 6.80 | N/A | N/A |
| PIMCO NEW YORK Municipal Income FUND | |||
| RSJN | 33.60 | -0.02 | -0.05% |
| FT Vest U.S. Eq Eq Wght Buffr ETF - Jun | |||
| PJP | 90.78 | -0.18 | -0.20% |
| Invesco Pharmaceuticals ETF | |||
COO and
Correlation & Price change
A.I.dvisor indicates that over the last year, COO has been loosely correlated with A. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if COO jumps, then A could also see price increases.